WAVE Life Sciences Ltd
WVE17.000USD
-0.150-0.87%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
2.72BMarket Cap
LossP/E TTM
More Details of WAVE Life Sciences Ltd Company
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
WAVE Life Sciences Ltd Info
Ticker SymbolWVE
Company nameWAVE Life Sciences Ltd
IPO dateNov 11, 2015
CEOBolno (Paul B)
Number of employees287
Security typeOrdinary Share
Fiscal year-endNov 11
Address7 Straits View
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySingapore
Postal code018936
Phone6562363388
Websitehttps://www.wavelifesciences.com/
Ticker SymbolWVE
IPO dateNov 11, 2015
CEOBolno (Paul B)
Company Executives of WAVE Life Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
60.96K
+143.86%
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
25.40K
-37.11%
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+48.58%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
12.70K
-33.66%
Dr. Paul B. Bolno, M.D.
Dr. Paul B. Bolno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
--
--
Dr. Gregory L. (Greg) Verdine, Ph.D.
Dr. Gregory L. (Greg) Verdine, Ph.D.
Director
Director
--
--
Dr. Peter Kolchinsky, Ph.D.
Dr. Peter Kolchinsky, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
60.96K
+143.86%
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
25.40K
-37.11%
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+48.58%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
12.70K
-33.66%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GSK plc
9.98%
RA Capital Management, LP
9.97%
Adage Capital Management, L.P.
7.97%
BlackRock Institutional Trust Company, N.A.
4.78%
Maverick Capital, Ltd.
4.59%
Other
62.71%
Shareholders
Shareholders
Proportion
GSK plc
9.98%
RA Capital Management, LP
9.97%
Adage Capital Management, L.P.
7.97%
BlackRock Institutional Trust Company, N.A.
4.78%
Maverick Capital, Ltd.
4.59%
Other
62.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.00%
Hedge Fund
21.22%
Investment Advisor/Hedge Fund
16.23%
Corporation
14.13%
Venture Capital
10.06%
Research Firm
1.89%
Individual Investor
0.41%
Bank and Trust
0.23%
Pension Fund
0.21%
Other
6.61%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
368
140.86M
88.47%
+5.01M
2025Q2
364
156.69M
98.46%
-1.61M
2025Q1
368
156.82M
101.38%
+1.16M
2024Q4
342
152.89M
100.27%
+6.14M
2024Q3
306
144.44M
97.59%
+25.71M
2024Q2
274
116.00M
94.13%
+429.46K
2024Q1
255
115.83M
95.69%
+2.66M
2023Q4
240
115.18M
98.42%
+19.70M
2023Q3
224
93.79M
97.86%
+5.83M
2023Q2
224
93.41M
97.80%
+7.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GSK plc
16.78M
10.54%
--
--
Jun 06, 2025
RA Capital Management, LP
18.21M
11.44%
+12.70K
+0.07%
Aug 11, 2025
Adage Capital Management, L.P.
15.02M
9.43%
+2.50M
+19.97%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.75M
5.5%
+540.89K
+6.59%
Jun 30, 2025
Maverick Capital, Ltd.
8.26M
5.19%
--
--
Jun 30, 2025
Driehaus Capital Management, LLC
6.53M
4.1%
+172.92K
+2.72%
Jun 30, 2025
Shin Nippon Biomedical Laboratories Ltd
5.71M
3.58%
--
--
Jun 06, 2025
M28 Capital Management LP
5.66M
3.56%
--
--
Jun 30, 2025
Emerald Advisers LLC
5.19M
3.26%
+130.23K
+2.57%
Jun 30, 2025
Kynam Capital Management LP
4.56M
2.86%
-339.44K
-6.93%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
1.81%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.34%
Global X Genomics & Biotechnology ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
iShares U.S. Pharmaceuticals ETF
0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
0.26%
iShares Micro-Cap ETF
0.19%
Franklin Genomic Advancements ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.14%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.81%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.34%
Global X Genomics & Biotechnology ETF
Proportion1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.85%
iShares U.S. Pharmaceuticals ETF
Proportion0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.26%
iShares Micro-Cap ETF
Proportion0.19%
Franklin Genomic Advancements ETF
Proportion0.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of WAVE Life Sciences Ltd?
The top five shareholders of WAVE Life Sciences Ltd are:
GSK plc holds 16.78M shares, accounting for 10.54% of the total shares.
RA Capital Management, LP holds 18.21M shares, accounting for 11.44% of the total shares.
Adage Capital Management, L.P. holds 15.02M shares, accounting for 9.43% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.75M shares, accounting for 5.50% of the total shares.
Maverick Capital, Ltd. holds 8.26M shares, accounting for 5.19% of the total shares.
GSK plc holds 16.78M shares, accounting for 10.54% of the total shares.
RA Capital Management, LP holds 18.21M shares, accounting for 11.44% of the total shares.
Adage Capital Management, L.P. holds 15.02M shares, accounting for 9.43% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.75M shares, accounting for 5.50% of the total shares.
Maverick Capital, Ltd. holds 8.26M shares, accounting for 5.19% of the total shares.
What are the top three shareholder types of WAVE Life Sciences Ltd?
The top three shareholder types of WAVE Life Sciences Ltd are:
GSK plc
RA Capital Management, LP
Adage Capital Management, L.P.
GSK plc
RA Capital Management, LP
Adage Capital Management, L.P.
How many institutions hold shares of WAVE Life Sciences Ltd (WVE)?
As of 2025Q3, 368 institutions hold shares of WAVE Life Sciences Ltd, with a combined market value of approximately 140.86M, accounting for 88.47% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.00%.
What is the biggest source of revenue for WAVE Life Sciences Ltd?
In --, the -- business generated the highest revenue for WAVE Life Sciences Ltd, amounting to -- and accounting for --% of total revenue.
